Skip to main content
OpenTrials

Clinical trial condition

Neoplasms by Histologic Type

Explore clinical trials studying Neoplasms by Histologic Type. Study availability and eligibility vary by location and protocol.

83 public trials 25 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms by Histologic Type trial results

Active, not recruiting

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT03155191

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Akita University Hospital Akita, Japan
  • University Of Fukui Hospital Yoshida, Fukui, Japan
  • Kyushu University Hospital Higashiku, Fukuoka, Japan
  • Hokkaido University Hospital Sapporo, Hokkaido, Japan
View Trial Details
Active, not recruiting

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

NCT04807166

Conditions
Adnexal Diseases, Angiogenesis, Anlotinib, +22 more
Locations
  • Huai'an First People's Hospital Huai'an, China
  • Nanjing Drum Tower Hospital Nanjing, China
  • Zhongda Hospital Southeast University Nanjing, China
  • The First Affiliated Hospital of Soochow University Suzhou, China
View Trial Details
Completed

DPX-Survivac and Checkpoint Inhibitor in DLBCL

NCT03349450

Conditions
Adult Diffuse Large Cell Lymphoma, Adult Refractory Diffuse Large B-Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, +18 more
Locations
  • Tom Baker Cancer Centre - Alberta Health Services Calgary, Alberta, Canada
  • Nova Scotia Health Authority: Queen Elizabeth II Health Sciences Centre Halifax, Nova Scotia, Canada
  • London Health Sciences Centre London, Ontario, Canada
  • Ottawa Hospital Research Institute Ottawa, Ontario, Canada
View Trial Details
Completed

A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies

NCT04544748

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +30 more
Locations
  • SAHI "Republican Clinical Oncological Dispensary of the Ministry of Health of the Republic of Tatarstan" Kazan', Russia
  • FSBI "N.N. Blokhin National Medical Research Center of Oncology"of the Ministry of Health of the Russian Federation Moscow, Russia
  • FSBI "Russian Scientific Center of Roentgenoradiology" of the Ministry of Health of the Russian Federation Moscow, Russia
  • FSAEI HE "I.M. Sechenov First Moscow State Medical University" of the Ministry of Health of Russian Federation Moscow, Russia
View Trial Details
Completed

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

NCT02158858

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Disease, +23 more
Locations
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • UCLA Medical Center Los Angeles, California, United States
  • Mayo Clinic Jacksonville Jacksonville, Florida, United States
  • Northwestern University - Lurie Comprehensive Cancer Center Chicago, Illinois, United States
View all 48 locations
View Trial Details
Completed

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

NCT02467270

Conditions
Bone Marrow Diseases, Chronic Disease, Disease Attributes, +12 more
Locations
  • Emory University Winship Cancer Institute Atlanta, Georgia, United States
  • Indiana Blood & Marrow Transplantation Indianapolis, Indiana, United States
  • University of Maryland Medical Center Baltimore, Maryland, United States
  • Michigan Medicine Ann Arbor, Michigan, United States
View all 86 locations
View Trial Details
Completed

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

NCT05228470

Conditions
BCMA, BCMA-CD3 Bispecific, Bispecific, +23 more
Locations
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Guangdong Provincial People's Hospital Guangzhou, Guangdong, China
  • Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
View all 15 locations
View Trial Details
Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

NCT03037385

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Diseases, +55 more
Locations
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • UC Irvine Medical Center Orange, California, United States
  • University of Colorado Anschutz Medical Campus Aurora, Colorado, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
View all 71 locations
View Trial Details

Related conditions